Sobi is an international biotechnology company dedicated to innovative treatments for rare diseases and niche indications. The company was first to market outside the U.S. with a long-acting haemophilia A treatment and today has a leading haemophilia franchise.
Sobi has delivered strong operational performance and shareholder return over the last years driven primarily by the successful haemophilia launch in Europe. During 2018, Sobi broadened the portfolio and strengthened its immunology business through the acquisitions of the global rights to Gamifant and the US rights to Synagis.
The continued building of a strong haemophilia business, broadening of the product portfolio and successful integration of the recently acquired Synagis and Gamifant, are key for future value creation.